Mergers & Acquisitions - Mergers & Acquisitions, Rare diseases

Filter

Popular Filters

1 to 25 of 32 results

UPDATE: AstraZeneca divests Myalept for $325 million

06-11-2014

Anglo-Swedish pharma major AstraZeneca today announced that it has entered into a definitive agreement…

Aegerion PharmaceuticalsAstraZenecaMergers & AcquisitionsMyaleptPharmaceuticalRare diseases

Endo’s buy of struggling Auxilium for $2.6 billion analysed by GlobalData

12-10-2014

Endo International’s $2.6 billion purchase of Auxilium Pharmaceuticals (The Pharma Letter October 9)…

Auxilium PharmaceuticalsEndo InternationalMen's HealthMergers & AcquisitionsPharmaceuticalRare diseasesTestimTestopelXiaflex

Avalon Ventures and GlaxoSmithKline launch two new companies

23-09-2014

Avalon Ventures today announced the launch of two new companies formed through its collaboration with…

Avalon VenturesFinancialGlaxoSmithKlineHematologyMergers & AcquisitionsPharmaceuticalRare diseasesSilarus TherapeuticsThyritope Biosciences

Oncothyreon acquires Alpine Biosciences

Oncothyreon acquires Alpine Biosciences

12-08-2014

US biotech firm Oncothyreon says that it has acquired Alpine Biosciences, of Seattle, Washington, a privately…

Alpine BiosciencesBiotechnologyBusiness FinanceImmunotherapyMedicineMergers & AcquisitionsOncologyOncothyreonRare diseasesUSA

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

Retrophin proposes acquisition of Clinuvel Pharma for $95 million

28-07-2014

The USA’s Retrophin has submitted an unsolicited $95 million takeover proposal to the board of directors…

AfamelanotideAustraliaClinuvel PharmaceuticalsDermatologicalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinScenesse

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Baxter buys AesRx, gaining rights to investigational SCD drug

Baxter buys AesRx, gaining rights to investigational SCD drug

10-07-2014

US drugmaker Baxter International said yesterday that it has acquired AesRx, a private US biopharmaceutical…

Aes-103AesRxBaxter InternationalBiotechnologyHematologyMergers & AcquisitionsRare diseasesUSA

Shire acquires Lumena Pharma, adding to rare disease portfolio

Shire acquires Lumena Pharma, adding to rare disease portfolio

12-05-2014

Ireland-headquartered drugmaker Shire says it will acquire San Diego, USA-based rare disease focussed…

Lumena PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesShire

Riemser Pharma acquires French drugmaker Keocyt

12-05-2014

German specialty pharmaceutical company Riemser Pharma (formerly Riemser Arzneimittel) said today that…

KeocytMergers & AcquisitionsOncologyPharmaceuticalRare diseasesRiemser Pharma

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

16-04-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget today announced their intention…

belinostatBioAlliance PharmaLivatagMergers & AcquisitionsOncologyPharmaceuticalRare diseasesTopotarget

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

Prothelia and Alexion partner with University of Nevada for ultra-rare neuromuscular disorder

17-02-2014

Privately-held USA-based Prothelia and the University of Nevada, Reno, have entered into strategic agreements…

Alexion PharmaceuticalsMergers & AcquisitionsPharmaceuticalProtheliaRare diseasesResearch

Retrophin to acquire Manchester Pharma in $62.5 million deal

Retrophin to acquire Manchester Pharma in $62.5 million deal

13-02-2014

USA-based Retrophin has signed an agreement to acquire Manchester Pharmaceuticals, a privately-held specialty…

Cardio-vascularChenodalManchester PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesRetrophinVecamyl

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Forest Labs to spend $2.9 billion on acquiring Aptalis

Forest Labs to spend $2.9 billion on acquiring Aptalis

09-01-2014

Confirming recent speculative reports, US drugmaker Forest Laboratories says it has entered into a definitive…

AptalisForest LaboratoriesGastro-intestinalsMergers & AcquisitionsPharmaceuticalRare diseases

Italy’s Gentium accepts $1 billion takeover offer from Jazz Pharma

20-12-2013

Ireland-headquartered drugmaker Jazz Pharmaceuticals has entered into a definitive agreement to acquire…

defibrotideDefitelioGentiumItalyJazz PharmaceuticalsMergers & AcquisitionsNephrology and HepatologyPharmaceuticalRare diseases

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

22-11-2013

US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

Shire strengthens position in rare diseases with $4.2 billion buy of ViroPharma

11-11-2013

Ireland-based drugmaker Shire saw its share rise 2.2% to £33.16 shortly after markets opened this morning,…

CinryzeFirazyrMergers & AcquisitionsPharmaceuticalRare diseasesShireViroPharma

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

Salix Pharma moves into diabetes with $2.6 billion buy of Santarus

08-11-2013

Salix Pharmaceuticals has entered into a definitive merger agreement to acquire all the outstanding common…

DiabetesGastro-intestinalsGlumetzaMergers & AcquisitionsPharmaceuticalRare diseasesRuconestSalix PharmaceuticalsSantarus

Chiesi expands rare disease portfolio with acquisition

26-08-2013

Privately-owned Italian drugmaker Chiesi Group has signed, through its UK affiliate, a definitive agreement…

BiotechnologyChiesi FarmaceuticiLamazymMergers & AcquisitionsPharmaceuticalRare diseasesZymenex

Zambon to acquire UK respiratory specialist Profile Pharma

10-06-2013

Family-owned Italian drugmaker Zambon has taken a significant step to grow in the respiratory therapy…

Mergers & AcquisitionsPharmaceuticalProfile PharmaPromixinRare diseasesRespiratory and PulmonaryZambon

Shire acquires Premacure to expand in new therapy area

13-03-2013

In a second acquisition so far this year, Ireland-headquartered drugmaker Shire (LSE: SHP) said on Tuesday…

BiotechnologyMergers & AcquisitionsOphthalmicsPharmaceuticalPremacureRare diseasesShire

Shire to acquire Lotus Tissue Repair for undisclosed price

09-01-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire…

BiotechnologyLotus Tissue RepairMergers & AcquisitionsPharmaceuticalRare diseasesShire

1 to 25 of 32 results

Back to top